Markets

Intellia Therapeutics prices upsized IPO at $18, the high end of the range

Intellia Therapeutics, a preclinical biotech developing gene editing therapies using CRISPR/Cas9 technology, raised $108 million by offering 6 million shares at $18, the high end of the range of $16 to $18. Intellia Therapeutics plans to list on the Nasdaq under the symbol NTLA. Credit Suisse, Jefferies and Leerink Partners acted as lead managers on the deal.

The article Intellia Therapeutics prices upsized IPO at $18, the high end of the range originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NTLA

Other Topics

IPOs

Latest Markets Videos